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Background: The purpose of this study was to investigate the endometrial safety of an oral 
contraceptive containing estradiol valerate/dienogest (E2V/DNG) administered as an estrogen 
step-down and progestogen step-up regimen in women of reproductive age (18–50 years), using 
histological assessment of endometrial biopsy samples.
Methods: Endometrial biopsies were taken in a subset of healthy women who took part in a 
multicenter, open-label, noncomparative study assessing the contraceptive efficacy and safety of 
an E2V/DNG oral contraceptive. In each 28-day cycle, women received E2V 3 mg on days 1–2, 
E2V 2 mg/DNG 2 mg on days 3–7, E2V 2 mg/DNG 3 mg on days 8–24, E2V 1 mg on days 25–26, 
and placebo on days 27–28. Women underwent endometrial biopsy between days 12 and 19 of 
the cycle, both at screening and at cycle 20 (or at the final examination).
Results: Of the 283 women who underwent an endometrial biopsy at screening, 218 under-
went a follow-up biopsy at cycle 20. At screening, abnormal biopsy results, both classified as 
“simple hyperplasia without atypia”, were seen in two women, who were withdrawn from the 
trial. At cycle 20, there were no abnormal findings of endometrial hyperplasia or malignancy, 
and 80.9% of women had atrophic, inactive, or secretory endometrium.
Conclusion: After 20 cycles of treatment, an oral contraceptive containing E2V and DNG is 
safe and effective to transform the endometrium into a secretory/inactive or atrophic status, and 
exhibits no deleterious effects on endometrial histology in women aged 18–50 years.
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Introduction
The use of combined oral contraceptives is associated with distinct changes in the 
histology of the endometrium. Such changes include the inhibition of glandular growth 
and differentiation, resulting in an inactive or atrophic endometrium in many users.1–4 
In addition to inhibition of ovulation, these changes contribute to the contraceptive 
efficacy of combined oral contraceptives, creating a thin, flat endometrium. While 
combined oral contraceptives contain both an estrogen and a progestogen component, 
the overall effect of combined oral contraceptives on the endometrium is considered 
to be attributable to the progestogen component,5,6 the effects of which are mediated 
via the progesterone receptor.7
Dienogest (DNG) is one of several new progestogens that have been introduced 
in recent decades.8 It is a specific progesterone receptor agonist7 and combines the 
properties of both 19-nortestosterone derivatives and progesterone derivatives.9 
  Consequently, DNG has a unique pharmacological profile and a pronounced effect 
on the endometrium.7,9,10International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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DNG 2 mg (Visanne®; Bayer HealthCare Pharmaceuticals,   
Germany) is indicated for the treatment of endometriosis. 
At this same dose, DNG also represents the progestogen 
component of a combined oral contraceptive containing 
ethinylestradiol 30 µg and of a continuous hormone replace-
ment therapy containing estradiol valerate (E2V) 2 mg. Both 
preparations are highly effective in their respective indica-
tions, and are well tolerated and associated with a favorable 
bleeding profile.11–14 Attempts to develop estradiol-containing 
combined oral contraceptives have historically been character-
ized by suboptimal cycle stability and bleeding irregularities, 
particularly when administered as monophasic or biphasic 
regimens,15–19 although excellent contraceptive efficacy in 
clinical studies has been achieved.15–20 More recently, a novel 
oral contraceptive comprising DNG and E2V in a dynamic 
estrogen step-down and progestogen step-up dosing regimen 
has become available in many countries worldwide. This 
regimen comprises an extended hormone-containing phase 
(26 days), including four days of unopposed estrogen delivery, 
and a shortened hormone-free interval (two days). The E2V/
DNG oral contraceptive has been shown in clinical trials to be 
an effective contraceptive that is well tolerated and associated 
with a good bleeding profile.21,22
This study was designed to investigate the contraceptive 
efficacy, safety, and tolerability of the E2V/DNG regimen in 
1377 women of reproductive age, using the preparation as an 
oral contraceptive; the primary findings of this trial have previ-
ously been reported.22 The E2V/DNG regimen was associated 
with an overall unadjusted Pearl Index of 0.73 and a well-
controlled and regular bleeding pattern. E2V/DNG was well 
tolerated and mean body weight generally remained stable 
throughout the study visits. A large majority of the women 
reported unchanged or improved physical and emotional 
well-being, compared with their pretreatment status, as well 
as a high degree of overall satisfaction with the study drug.
The importance of investigating endometrial changes in 
women using new combined oral contraceptives as indicators 
for the development of endometrial cancer is reflected in the 
European Medicines Agency Guideline on Clinical Inves-
tigations of Steroid Contraceptives in Women.23 Therefore, 
histological assessment of endometrial biopsy samples was 
undertaken in a subgroup of women aged 18–50 years to 
assess the endometrial safety of E2V/DNG.
Methods
Design and participants
The full methodological details of this trial have previously 
been reported.22 Briefly, this was a multicenter, open-label, 
noncomparative study of E2V/DNG, administered using 
an estrogen step-down and progestogen step-up dosing 
regimen. To assess the effect of the E2V/DNG regimen on 
the endometrium, endometrial histology was assessed in a 
subgroup of women from selected study centers who took 
part in this trial.
Healthy female volunteers (aged 18–50 years) requesting 
contraception, who had a body mass index of #30 kg/m2 
and a normal cervical smear test result, were included in 
this trial. Participants in the study were either new users of 
hormonal contraception or had switched from another oral 
  contraceptive. Exclusion criteria were generally consistent 
with the usual contraindications for combined oral contra-
ceptive use. The use of long-acting hormonal contraception 
immediately prior to the study was not permitted. In   addition, 
no endometrial biopsies were taken from women with an 
acute genital infection, as diagnosed at the discretion of the 
investigator. Women in the endometrial biopsy subgroup 
discontinued the study if the screening biopsy revealed 
relevant pathology.
Treatment
Women participating in this trial received treatment for a 
total of 20 cycles. Each 28-day cycle comprised E2V 3 mg on 
days 1–2, E2V 2 mg/DNG 2 mg on days 3–7, E2V 2 mg/DNG 
3 mg on days 8–24, E2V 1 mg on days 25–26, and placebo 
on days 27–28. One tablet was taken daily with no tablet-free 
interval between cycles. In the first treatment cycle, the first 
tablet was taken on the first day of menstrual or withdrawal 
bleeding.
Assessments
Endometrial biopsies were taken between days 12 and 19 of 
the cycle, both at screening (including during active use of 
another oral contraceptive prior to switching to treatment with 
E2V/DNG at visit 2) and at cycle 20 (or at a final examination 
if women prematurely discontinued the study between cycles 
6 and 20). If insufficient tissue was obtained, the biopsy was 
repeated within four weeks.
Endometrial biopsies were taken with a pipelle and did 
not require dilation of the cervix or anesthesia. Endometrial 
material was obtained from the anterior or posterior wall 
of the fundus area. Material taken from the tubal corner 
or the endocervix was deemed inappropriate, and was not 
used. The Laboratorium für Klinische Forschung (LKF), 
Kiel, Germany was responsible for providing materials 
and organizing logistics. For the evaluation of endometrial 
biopsies, the specimens were sent to LKF. One pathologist International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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Table 1 Histological categories for evaluation of endometrial 
biopsies
Histological categories
Insufficient 
material
Normal biopsy  
results
Abnormal biopsy 
results
no tissue Atrophica simple hyperplasia 
without atypia
Tissue insufficient 
for diagnosis
Inactive simple hyperplasia 
with atypia
Proliferative 
  Weakly proliferative 
  Actively proliferativeb 
  Disordered proliferativec
complex hyperplasia 
without atypia
secretory 
  cyclic type 
  Progestational type
complex hyperplasia 
with atypia
Menstrual type carcinoma
Notes:  aIncludes  cases  with  sufficient  atrophic  epithelial  strips  without  intact 
glands or stroma; bActively proliferative endometrium has numerous mitoses, but 
lacks  secretory  or  metaplastic  changes;  cDisordered  proliferative  endometrium 
describes the cystic dilation of randomly scattered glands dispersed within the array 
of normally present proliferative cells, gland density is not changed and occasional 
glands may have some branching. This differs from endometrial hyperplasia, which is 
defined as proliferation of glands of irregular size and shape with an accompanying 
increase in the glands:stroma ratio.24
Table 2 Endometrial biopsy diagnosis, classified by histological 
description,  at  screening  and  at  final  examination  (full  biopsy 
analysis set)
Screening  
(visit 1)  
(n = 283)
Final examination 
(visit 8) 
(n = 219)
n (%) n (%)
normal 
endometrium
253 89.4 204 93.2
  Atrophic 50 17.7 54 24.7
  Inactive 50 17.7 86 39.3
  Proliferative
    Weakly 
proliferative
29 10.2 18 8.2
    Actively 
proliferative
15 5.3 3 1.4
    Disordered 
proliferative
81 28.6 4 1.8
  Secretory
  cyclic type 16 5.7 14 6.4
    Progestational 
type
6 2.1 23 10.5
    Menstrual 
type
1 0.4 1 0.5
Abnormal 
endometrium
2 0.7 0 0
not assessable 28 9.9 14 6.4
not taken 0 0 1 0.5
(reader) assessed the samples. Thereafter, the samples were 
stored at LKF to enable a rereading procedure at a later time 
point, if   necessary. To evaluate the endometrial safety of 
E2V/DNG, each endometrial biopsy sample was classified 
according to one of three categories, ie, insufficient   material, 
normal/nonsuspicious, or abnormal. Histological catego-
ries for the evaluation of the endometrium are described 
in Table 1.
statistical analysis
For this prospectively defined subgroup analysis, endome-
trial biopsies were planned to be taken in a subgroup of 
250 women at screening and at the final examination.   Taking 
into consideration a dropout rate of 40% over 20 cycles, 
which is typically observed in long-term studies of oral 
contraceptives, approximately 150 biopsies were aimed to 
be available at cycle 20. No formal sample-size calculation 
for the number of biopsy samples was performed. Biopsy 
results are presented as a percentage of the total number of 
assessments.
Results
subject disposition
A total of 1377 women were included in the study. 
  Endometrial biopsies were taken in 283 of these women at 
screening. An endometrial biopsy was undertaken in 218 of 
these women at a final examination. In this subgroup, 22.4% 
of women were new oral contraceptive users and 67.3% were 
switchers from another oral contraceptive.
endometrial histology
A summary of endometrial biopsy samples, classified by 
histological description, at screening and at the final exami-
nation is presented in Table 2. Abnormal biopsy findings at 
screening were seen in two women (both classified as “simple 
hyperplasia without atypia”). These women were therefore 
prematurely withdrawn from the study.
Of the normal endometrial biopsies observed at the 
screening visit, the majority were of the “proliferative” type. 
Just over one-third of biopsies (35.4%) were “atrophic” or 
“inactive”. At the final examination, there were no abnormal 
findings of endometrial hyperplasia or malignancy. Normal 
endometrial biopsy results were seen in 204 women (93.2%). 
Nonassessable results were recorded in 14 women (6.4%). 
Overall, 24.7% of the normal biopsies at the final examination 
time point were “atrophic”, 39.3% were “inactive”, 11.4% 
were of the “proliferative” type (weakly [8.2%], disordered 
[1.8%], or actively [1.4%]), 16.9% were of the “secretory” 
type (progestational [10.5%] or cyclic [6.4%]), and 0.5% 
were of the “menstrual” type. In total, 80.9% of women had 
an atrophic, inactive or secretory endometrium.International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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There were five women with a diagnosis of endometrial 
polyps at screening. The polyps were classified as “atrophic” 
in three women and as “functional” in two women. In all five 
women, a biopsy was taken at the final examination. There 
were no women with signs of endometrial polyps at the final 
examination. Signs of limited focal endometrial metaplasia 
on a background of inactive endometrium were observed in 
four women overall; two women at the time of screening 
and two at the final examination. In all cases, there were no 
abnormal findings of endometrial hyperplasia.
Discussion
The results of this prospectively defined subgroup analysis 
demonstrate the endometrial safety of E2V/DNG admin-
istered in an estrogen step-down and progestogen step-up 
regimen, including four days of unopposed estrogen. After 
20 cycles of treatment, endometrial biopsies revealed an inac-
tive or atrophic endometrium in 64% of women. Of note, no 
findings of hyperplasia or malignancy were observed during 
20 cycles of treatment.
Estrogen exerts a stimulatory effect on the endometrium, 
and long-term unopposed exposure to even low doses is 
associated with a substantial risk of abnormal endometrial 
growth, as has been extensively reviewed previously.24 
Indeed, the administration of unopposed estrogen to post-
menopausal women has been associated with an increased 
risk of endometrial hyperplasia25 and endometrial cancer.26 
Although the E2V/DNG oral contraceptive used in the cur-
rent study includes four days (days 1–2 and days 25–26) of 
unopposed E2V , there was no evidence of an increase in the 
incidence of endometrial hyperplasia. These results support 
data from previous studies of combined oral contraceptives, 
which did not observe any changes that could be described 
as hyperplasic or malignant.27–30
The stimulatory effect of estrogen on the endometrium 
is opposed by progestogens, which inhibit estrogen-induced 
endometrial proliferation. In the current subgroup analysis, 
good suppression of endometrial activity was observed. 
Furthermore, endometrial suppression was evident at a time 
point of the treatment cycle between day 12 and day 19, when 
the proliferative stimulation by the estrogenic compound is 
expected to approach its maximum level. DNG is a selective 
progesterone receptor agonist that has potent endometrial 
activity when administered orally.7 DNG exerts a potent 
progestogenic effect at the level of the   endometrium, counter-
acting estrogenic activity. In postmenopausal women receiv-
ing estrogen, this results in protection of the   endometrium.31 
Furthermore, it is important to know the effect of a new 
contraceptive formulation on the endometrium because 
endometrial function also plays an important role in the 
uterine bleeding process.
The results of the current subgroup analysis are com-
parable with those of a limited number of studies that have 
assessed the endometrial effects of other cyclic or extended 
low-dose combined oral contraceptives.2,4,27–30 In a study 
by Anderson et al, women received a 91-day extended 
regimen of ethinylestradiol 30 µg/levonorgestrel 150 µg 
that provided low-dose estrogen (10 µg) instead of pla-
cebo during the typical seven-day hormone-free interval.27 
  During active treatment, 70% of women had an inactive or 
atrophic endometrium. Similarly, after 13 cycles of treat-
ment with ethinylestradiol 30 µg/drospirenone 3 mg in a 
21-day regimen with a seven-day tablet-free period, 63% 
of women had an atrophic endometrium.2 Also, histologi-
cal and ultrasonographical evaluations confirmed that the 
proliferative activity of the endometrium was suppressed 
by this oral contraceptive treatment. Furthermore, no 
adverse endometrial effects were observed after 13 cycles 
of a continuous combined oral contraceptive regimen 
  (ethinylestradiol 20 µg/  levonorgestrel 90 µg); 52% of 
women receiving this regimen had endometrial histology 
results categorized as “other”, which primarily included 
an inactive or benign endometrium.29 In another study, no 
adverse endometrial effects were observed among women 
who received a 21-day ethinylestradiol 20 µg/  desogestrel 
150 µg regimen with a reduced hormone-free interval and 
five days of unopposed estrogen treatment (placebo was 
administered on days 22–23, followed by ethinylestradiol 
10 µg on days 24–28).28 In a recent study by Rabe et al, 
59 women underwent endometrial biopsy to examine the 
effect of ethinylestradiol 0.02 mg/chlormadinone acetate 
2 mg administered in a 24/4-day regimen on endometrial 
histology. After six treatment cycles, ethinylestradiol 
0.02 mg/chlormadinone acetate 2 mg demonstrated effec-
tive and reversible endometrial effects without exerting 
any pathological effects. At cycle 6, 16% of subjects had a 
secretory and 60% an inactive endometrium.30
The use of estradiol as the only estrogen component in 
combined oral contraceptives has so far not been successful 
because it has been characterized by suboptimal cycle stability 
and bleeding irregularities, particularly when administered as 
monophasic or biphasic regimens.15–19 This can be explained 
by local enzymes (eg, 17ß-hydroxysteroid dehydrogenase) 
which, in the presence of a progestogen, are stimulated within 
the endometrial cells, causing rapid oxidation of estradiol 
to estrone.32 Therefore, the local level of estradiol is also International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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reduced, which may cause the incidence of intermenstrual 
bleeding to increase. Furthermore, sequential preparations 
are known to improve cycle stability in women experienc-
ing bleeding irregularities. Early estrogenic dominance is 
hypothesized to ensure initial endometrial proliferation and 
sensitivity for mid-cyclic progestogen action and endometrial 
stroma stability, particularly towards the end of the cycle.21 
To ensure estrogen dominance in the first cycle phase, ie, 
the stage at which the proliferation of the endometrium is 
promoted under estrogen influence, E2V was administered 
on days 1–26 of the cycle at doses stepped down from 3 mg 
to 1 mg. Essentially, the shortened hormone-free interval to 
only two days, the progestogen dominance in the mid-to-late 
part of the cycle, and the estrogen-only phase before and at 
the end of the progestogen phase were expected to increase 
the cycle stability.
It has been shown previously that E2V/DNG in the pres-
ent formulation is associated with a bleeding pattern and 
cycle control profile that is comparable with that of a low-
dose ethinylestradiol-containing oral contraceptive.21 In the 
present study, the overall frequency of women experiencing 
withdrawal bleeding was relatively stable throughout the 
treatment cycles, ranging between 76.8% and 81.6% dur-
ing cycles 1–19. Furthermore, only 0.1% of 1377 women 
discontinued the study medication prematurely due to the 
absence of withdrawal bleeding.
The number of women with intracyclic bleeding decreased 
during the course of the study from 24.0% during cycle 2 
and reaching the lowest level of 10.2% during cycle 18. In 
general, there were fewer women with intracyclic bleeding 
episodes during the second half of the study compared with 
the first half of the treatment cycles. Only 2.5% of women 
prematurely discontinued study medication due to menstrual 
bleeding irregularities.
The results of this analysis are reassuring on several 
counts. Firstly, this is one of the largest and longest studies 
assessing endometrial histology with combined oral contra-
ceptives in women of childbearing age, and the study was 
conducted over a period of up to 20 cycles. Also, this study 
population included women aged 18–50 years and, therefore, 
included women in their late reproductive years who might 
be at an increased risk of endometrial pathology.
At screening, almost one-half of the normal biopsy 
samples were “proliferative”, while one-third of normal 
samples were “atrophic” or “inactive”. This reflects the het-
erogeneous group of women that were included in the study, 
which consisted of new users of hormonal contraception (ie, 
spontaneously cycling women) and women switching from 
other oral contraceptive. At the final examination, only 11.4% 
of the normal biopsies were of the “proliferative” type.
Endometrial polyps were observed in five women at 
screening and in no women at the final examination. It is not 
possible to claim that the use of E2V/DNG is associated with 
a decrease in endometrial polyps, but no additional cases of 
polyps were detected, suggesting that the preparation does 
not have a deleterious effect in this setting. It should be noted 
that it is not possible to ensure, by performing an endome-
trial biopsy, that each and every polyp had disappeared. 
  However, small polyps are not a contraindication for the use 
of E2V/DNG or low-dose oral contraceptives in general.
Consistent with results reported for other low-dose 
combined oral contraceptives, this prospectively defined 
subgroup analysis demonstrated that an oral contraceptive 
containing E2V and DNG is safe and effective to transform 
the endometrium to a secretory/inactive or atrophic status and 
exhibits no deleterious effects on the endometrium of women 
aged 18–50 years during 20 cycles of treatment.
Acknowledgments
The authors would like to thank Dr Lutz Riethdorf and 
Dr Wolfgang Krause, the study pathologists, for their help 
in conducting the endometrial biopsy analyses.
Disclosure
This study, including medical writing support provided 
by Anna Mett of inScience Communications, a Wolters 
Kluwer business, was funded by Bayer HealthCare 
Pharmaceuticals.
JB has acted as a consultant to or received honoraria 
from Bayer HealthCare Pharmaceuticals, Schering Plough, 
Grünenthal, Procter and Gamble, and Lilly, and has received 
grants from Grünenthal, Bayer HealthCare Pharmaceuticals, 
Organon, Lilly, Schering Plough, Pfizer, Solvay, and Novo 
Nordisk. TR is a consultant and speaker for Bayer HealthCare 
Pharmaceuticals. SP and MS are current employees of Bayer 
HealthCare Pharmaceuticals.
References
1.  Oosterbaan HP. An open-label study of the effects of a 24-day regimen 
of gestodene 60 microg/ethinylestradiol 15 microg on endometrial his-
tological findings in healthy women. Eur J Contracept Reprod Health 
Care. 1999;4 Suppl 2:3–8.
2.  Ludicke F, Johannisson E, Helmerhorst FM, Campana A, Foidart J, 
Heithecker R. Effect of a combined oral contraceptive containing 3 mg 
of drospirenone and 30 microg of ethinyl estradiol on the human 
  endometrium. Fertil Steril. 2001;76(1):102–107.
3.  Anderson FD, Hait H, Hsiu J, Thompson-Graves AL, Wilborn WH, 
Williams RF. Endometrial microstructure after long-term use of a 91-day 
extended-cycle oral contraceptive regimen. Contraception. 2005;71(1): 
55–59.International Journal of Women’s Health
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/international-journal-of-womens-health-journal
The International Journal of Women’s Health is an international, peer-
reviewed open-access journal publishing original research, reports, 
reviews and commentaries on all aspects of women’s healthcare includ-
ing gynecology, obstetrics, and breast cancer. Subject areas include: 
Chronic conditions (migraine headaches, arthritis, osteoporosis); 
Endocrine and autoimmune syndromes; Sexual and reproductive 
health; Psychological and psychosocial conditions. The manuscript 
management system is completely online and includes a very quick 
and fair peer-review system. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.
International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
132
Bitzer et al
  4.  Coenen CM, Hollanders JM, Rolland R, Spielmann D, Bulten J. The 
effects of a low-dose gestodene-containing oral contraceptive on endo-
metrial histology in healthy women. Eur J Contracept Reprod Health 
Care. 1996;1(4):325–329.
  5.  Rowlands S. Newer progestogens. J Fam Plann Reprod Health Care. 
2003;29(1):13–16.
  6.  Williams CL, Stancel GM. Estrogens and Progestins. 9th ed. New York, 
NY: McGraw-Hill; 1996.
  7.  Sasagawa S, Shimizu Y, Kami H, et al. Dienogest is a selective 
progesterone receptor agonist in transactivation analysis with potent 
oral endometrial activity due to its efficient pharmacokinetic profile. 
Steroids. 2008;73(2):222–231.
  8.  Sitruk-Ware R. New progestagens for contraceptive use. Hum Reprod 
Update. 2006;12(2):169–178.
  9.  Oettel M, Breitbarth H, Elger W, et al. The pharmacological profile 
of dienogest. Eur J Contracept Reprod Health Care. 1999;4 Suppl 1: 
2–13.
  10.  Oettel M, Gräser T, Hoffmann H, Moore C, Zimmermann H, 
  Zimmermann T. The preclinical and clinical profile of dienogest.   
A short overview. Drugs Today. 1999;35 Suppl C:3–12.
  11.  Golbs S, Domhardt R, Radowicky S, Kaluzny Z, Wisser KH, 
  Zimmermann T. Clinical findings with the oral contraceptive combi-
nation ethinylestradiol/dienogest in Poland. Methods Find Exp Clin 
Pharmacol. 2002;24(9):585–592.
  12.  Graser T, Romer T, Wiedey KD, Janaud A. Climodien (estradiol valer-
ate 2 mg plus dienogest 2 mg) is safe and effective in the treatment of 
postmenopausal complaints. Climacteric. 2001;4(4):332–342.
  13.  Von Schoultz B. Clinical efficacy and safety of combined estradiol 
valerate and dienogest: A new no-bleed treatment. Climacteric. 2003; 
6 Suppl 2:24–32.
  14.  Zimmermann T, Dietrich H, Wisser KH, Hoffmann H. The efficacy 
and tolerability of Valette: A postmarketing surveillance study. Eur J 
Contracept Reprod Health Care. 1999;4(3):155–164.
  15.  World Health Organization Task Force on Oral Contraception. A ran-
domized, double-blind study of two combined oral contraceptives 
  containing the same progestogen, but different estrogens.   Contraception. 
1980;21(5):445–459.
  16.  Kivinen S, Saure A. Efficacy and tolerability of a combined oral contra-
ceptive containing 17 beta-estradiol and desogestrel. Eur J Contracept 
Reprod Health Care. 1996;1:183.
  17.  Schubert W, Cullberg G. Ovulation inhibition with 17 beta-estradiol 
cyclo-octyl acetate and desogestrel. Acta Obstet Gynecol Scand. 1987; 
66(6):543–547.
  18.  Serup J, Bostofte E, Larsen S, Westergaard J, Lebech PE. Natural 
oestrogens for oral contraception. Lancet. 1979;2(8140):471–472.
  19.  Wenzl R, Bennink HC, van Beek A, Spona J, Huber J. Ovulation inhibi-
tion with a combined oral contraceptive containing 1 mg micronized 
17 beta-estradiol. Fertil Steril. 1993;60(4):616–619.
  20.  Hirvonen E, Vartiainen E, Kulmala Y. A multicenter trial with a new OC 
using a natural estradiol and cyproterone acetate for women over 35. 
Adv Contracept. 1990;6(4):248.
  21.  Ahrendt HJ, Makalova D, Parke S, Mellinger U, Mansour D.   Bleeding 
pattern and cycle control with an estradiol-based oral contraceptive: 
A seven-cycle, randomized comparative trial of estradiol valerate/
dienogest and ethinyl estradiol/levonorgestrel. Contraception. 2009; 
80(5):436–444.
  22.  Palacios S, Wildt L, Parke S, Machlitt A, Romer T, Bitzer J. Efficacy 
and safety of a novel oral contraceptive based on oestradiol (oestradiol 
valerate/dienogest): a Phase III trial. Eur J Obstet Gynecol Reprod Biol. 
2010;149(1):57–62.
  23.  European Medicines Agency. Committee for Medicinal Products for 
Human Use. Guideline on clinical investigation of steroid contracep-
tives in women. EMEA/CPMP/EWP/519/98 Rev 1. London 2005:1–6. 
Available at: http://www.tga.gov.au/docs/pdf/euguide/ewp/051998enr1.
pdf. Accessed March 09, 2011.
  24.  Montgomery BE, Daum GS, Dunton CJ. Endometrial hyperplasia: 
A review. Obstet Gynecol Surv. 2004;59(5):368–378.
  25.  Furness S, Roberts H, Marjoribanks J, Lethaby A, Hickey M, Farquhar C. 
Hormone therapy in postmenopausal women and risk of endometrial 
hyperplasia. Cochrane Database Syst Rev. 2009(2):CD000402.
  26.  Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD.   
Postmenopausal hormone replacement therapy: Scientific review. 
JAMA. 2002;288(7):872–881.
  27.  Anderson FD, Feldman R, Reape KZ. Endometrial effects of a 91-day 
extended-regimen oral contraceptive with low-dose estrogen in place 
of placebo. Contraception. 2008;77(2):91–96.
  28.  Archer DF. Endometrial histology during use of a low-dose estrogen-
desogestrel oral contraceptive with a reduced hormone-free interval. 
Contraception. 1999;60(3):151–154.
  29.  Johnson JV , Grubb GS, Constantine GD. Endometrial histology fol-
lowing 1 year of a continuous daily regimen of levonorgestrel 90 micro   
g/ethinyl estradiol 20 micro g. Contraception. 2007;75(1):23–26.
  30.  Rabe T,  Hartschuh  E, Wahlstrom T,  Hoschen  K,  Konig  S.   
Endometrial safety of a novel monophasic combined oral contraceptive 
containing 0.02 mg ethinylestradiol and 2 mg chlormadinone acetate 
administered in a 24/4-day regimen over six cycles. Contraception. 
2010;82(4):358–365.
  31.  Graser T, Muller A, Mellinger U, Muck AO, Lippert TH, Oettel M. 
Continuous-combined treatment of the menopause with combinations 
of oestradiol valerate and dienogest – a dose-ranging study. Maturitas. 
2000;35(3):253–261.
  32.  Kuhnz W, Blode H, Zimmermann H. Pharmacokinetics of exogenous 
natural and synthetic estrogens and antiestrogens. In: Oettel M, 
  Schillinger E, editors. Handbook of Experimental Pharmacology. 
Berlin: Springer; 1999.